Akari Therapeutics Plc (NASDAQ: AKTX) is 12.97% higher on its value in year-to-date trading and has touched a low of $1.42 and a high of $4.21 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKTX stock was last observed hovering at around $2.29 in the last trading session, with the day’s loss setting it -0.2% off its average median price target of $5.00 for the next 12 months. It is also 58.2% off the consensus price target high of $5.00 offered by 1 analysts, but current levels are 58.2% higher than the price target low of $5.00 for the same period.
Currently trading at $2.09, the stock is -13.42% and -24.94% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing -8.73% at the moment leaves the stock -3.01% off its SMA200. AKTX registered 6.76% gain for a year compared to 6-month gain of 25.90%. The firm has a 50-day simple moving average (SMA 50) of $2.5997 and a 200-day simple moving average (SMA200) of $2.3115.
The stock witnessed a -17.72% loss in the last 1 month and extending the period to 3 months gives it a -12.92%, and is -13.99% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.75% over the week and 11.18% over the month.
Distance from 52-week low is 47.18% and -50.36% from its 52-week high.
Akari Therapeutics Plc (AKTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Akari Therapeutics Plc (AKTX) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Akari Therapeutics Plc is expected to release its quarterly report on 09/30/2021 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 41.20% this year.
Akari Therapeutics Plc (AKTX) Top Institutional Holders
17 institutions hold shares in Akari Therapeutics Plc (AKTX), with 11.01M shares held by insiders accounting for 28.62% while institutional investors hold 29.66% of the company’s shares. The shares outstanding are 26.28M, and float is at 20.63M with Short Float at 0.35%. Institutions hold 21.17% of the Float.
The top institutional shareholder in the company is NEA Management Company, LLC with over 0.45 million shares valued at $0.84 million. The investor’s holdings represent 1.18% of the AKTX Shares outstanding. As of Dec 30, 2020, the second largest holder is Omnia Family Wealth, LLC with 0.39 million shares valued at $0.72 million to account for 1.02% of the shares outstanding. The other top investors are United Asset Strategies, Inc. which holds 0.29 million shares representing 0.75% and valued at over $0.76 million, while Endurant Capital Management, LP holds 0.54% of the shares totaling 0.21 million with a market value of $0.38 million.
Akari Therapeutics Plc (AKTX): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 17.43% up over the past 12 months. Short interest in the company’s stock has risen 14.62% from the last report on Apr 14, 2021 to stand at a total of 71910.0 short shares sold with a short interest ratio of 0.24.